IQVIA Holdings Inc. $IQV Shares Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 137,065 shares of the medical research company’s stock after acquiring an additional 3,250 shares during the quarter. Jefferies Financial Group Inc.’s holdings in IQVIA were worth $30,896,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Claret Asset Management Corp boosted its position in shares of IQVIA by 1.1% in the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock worth $860,000 after buying an additional 49 shares during the period. Leonard Rickey Investment Advisors P.L.L.C. boosted its position in shares of IQVIA by 3.3% in the fourth quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock worth $409,000 after buying an additional 58 shares during the period. Brookstone Capital Management boosted its position in shares of IQVIA by 2.2% in the fourth quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock worth $661,000 after buying an additional 63 shares during the period. Private Advisor Group LLC boosted its position in shares of IQVIA by 1.0% in the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after buying an additional 63 shares during the period. Finally, Keybank National Association OH boosted its position in shares of IQVIA by 0.7% in the fourth quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock worth $2,052,000 after buying an additional 67 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE IQV opened at $168.28 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The business has a 50 day moving average price of $169.72 and a two-hundred day moving average price of $197.56. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a market cap of $28.09 billion, a PE ratio of 20.85, a price-to-earnings-growth ratio of 1.61 and a beta of 1.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same quarter last year, the firm earned $2.70 EPS. IQVIA’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its board has approved a share repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Truist Financial decreased their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. UBS Group decreased their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Friday, February 6th. BMO Capital Markets set a $250.00 target price on IQVIA in a research report on Friday, February 6th. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and upped their target price for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Finally, Jefferies Financial Group lowered their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $225.69.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.